In a crucial health update, new research has prompted the FDA to require GSK and Pfizer's RSV vaccines carry warnings of Guillain-Barré syndrome (GBS) risks. On Tuesday, January 7, it was reported that after a review of post market data, concerns were raised about increased GBS risks in patients who had received either Arexvy or Abrysvo vaccines from the respective pharmaceutical giants. While only Pfizer’s Abrysvo is available through the NHS , and UK packaging already includes the warning,

Tag-uri: Pfizer GSK